BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
15 januari, 2025
15 januari, 2025
BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.
Read the article at biostock.se:
Elicera’s candidate ELC-100 granted Orphan Drug Designation
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
15 januari, 2025
BioStock: Elicera’s candidate ELC-100 granted Orphan Drug Designation
Cell and gene therapy company Elicera Therapeutics has been granted Orphan Drug Designation (ODD) by the FDA for its drug candidate ELC-100, intended for the treatment of pancreatic neuroendocrine tumors. This highlights the potential of the oncolytic virus as a promising therapy for this challenging type of cancer.
Read the article at biostock.se:
Elicera’s candidate ELC-100 granted Orphan Drug Designation
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Investor
Aktieanalys
Fondernas investeringar
Svensk ekonomi
Volvo Cars jättesatsning
Investor
Aktieanalys
Fondernas investeringar
Svensk ekonomi
Volvo Cars jättesatsning
1 DAG %
Senast

OMX Stockholm 30
−0,94%
(17:13)
Munters
Idag, 14:51
Munters: Med en rejäl att-göra-lista
OMX Stockholm 30
1 DAG %
Senast
3 260,72